X

Stay Connected

Sign Up for Updates

network1.png

PPA strives to improve patient health, advance medical innovation and fuel economic growth.

LEARN MORE
network1.png

The PhRMA Foundation supports the research and career endeavors of scientists in drug discovery and development.

LEARN MORE
network1.png

Access Better Coverage educates consumers about the ABCs of health coverage and access to medicines.

LEARN MORE
network1.png

We Work For Health aims to increase awareness by uniting workers throughout the industry.

LEARN MORE
network1.png

Patent protection should always be considered by an inventor during the initial stages of their invention.

LEARN MORE
logo_white_MyOldMeds-New-1.png

Working to spread awareness and education about the importance of secure drug disposal.

LEARN MORE
LTAC_NEW21.png

Many Americans are struggling to afford their medicines and have important questions about their medicine costs. Let's Talk About Cost addresses these questions.

LEARN MORE
logo_white_LTAM.png

There are a lot of conversations in Washington about how to change Medicare Part D, but they aren't always focused on what seniors care about most: affordability and predictability.

LEARN MORE
 
We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

Word of the Month: 340B covered entity

By Nicole Longo  |    August 29, 2022
What is a 340B covered entity?   Read More

Making coupons count for patients at the pharmacy counter

By Katie Koziara  |    August 25, 2022
Too many patients face high out-of-pocket costs for brand medicines, even when they have insurance.   Read More

Frazier PhRMA Scholarship awarded to four college-bound students in Philadelphia and DC

By Rachel Weissman  |    August 22, 2022
The Kenneth C. Frazier PhRMA Scholars Program is going strong in 2022—and we are expanding our horizons to a new city. This summer, we are thrilled to announce four new recipients: Arianna...   Read More

ICYMI: New research builds upon growing body of evidence on value of COVID-19 treatments and vaccines

By Andrew Powaleny  |    August 16, 2022
Innovative biopharmaceutical research companies have been dedicated to fighting COVID-19 for over two years. Since the start of the pandemic, America’s biopharmaceutical companies have worked around...   Read More

Insulin and reconciliation

By Brian Newell  |    August 15, 2022
With Congress sending to the president a partisan reconciliation spending bill, the cost of insulin is receiving greater attention. Numerous proposals have been introduced in recent months aimed at...   Read More

New survey: Voters seriously concerned about fine print in reconciliation bill

By Mark Keida  |    August 12, 2022
With a final vote in Congress expected on a reconciliation spending bill, a new Morning Consult survey explores what this legislation actually does – and does not do – and finds that voters are...   Read More

This week’s reading list: All the reasons the Senate-passed drug pricing bill is bad policy

By Nicole Longo  |    August 10, 2022
Last weekend, the Senate passed the Inflation Reduction Act which includes dangerous price-setting provisions. The bill now heads to the House for consideration, where it is not too late for them to...   Read More

Value assessment should include all aspects of value that matter to patients

By Emilie Signora  |    August 10, 2022
We need to move toward a more value-driven health care system that centers around patients’ needs. Sound evidence can help guide us toward that, and we’re committed to developing tools to help...   Read More

Making coupons count for patients with HIV

By Emilie Signora  |    August 8, 2022
Despite having insurance, too many patients with HIV face high out-of-pocket costs for brand medicines. This is largely driven by insurer-imposed barriers that shift the cost of life-saving care onto...   Read More

Myth vs. Fact: The Senate’s latest price setting proposal

By Nicole Longo  |    August 5, 2022
The narratives being built around the Senate’s latest price setting proposal frame it as a bill intended to lower drug prices for patients and address rising inflation. But those narratives aren’t...   Read More

An open letter to Congress: Stand with patients and future cures

By Stephen J. Ubl  |    August 4, 2022
I recently joined PhRMA board members in penning the letter below to Congress, urging them to abandon their latest drug pricing proposal. You can read the letter here or below:   Read More

ICYMI: Patients across the country are sharing concerns about government price setting

By Matthew Norawong  |    August 3, 2022
As members of Congress continue to push forward misguided government price-setting policies under the guise of “negotiation,” patient advocates across the country have been speaking out in local...   Read More

The Senate’s latest price setting proposal will undermine U.S. economic growth

By Nicole Longo  |    August 3, 2022
Last week, we examined ways the latest drug pricing proposal will undermine patient access to medicines, American medical innovation and our health care system as a whole. But there is another...   Read More

Celebrating Medicare’s 57th anniversary

By Gabby Migliara  |    August 2, 2022
In case you missed it, Saturday, July 30, marked the anniversary of Medicare. For 57 years, Medicare has helped pay for medical care for Americans over the age of 65, as well as younger Americans...   Read More

New analysis finds deeper impact of drug pricing bill on biopharmaceutical researchers

By Brian Newell  |    August 1, 2022
A new analysis by the health care analytics and research firm Avalere reveals the partisan drug pricing bill will have a much deeper impact on the biopharmaceutical research industry than previously...   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Contributor

View Posts by Date

see all

Subscribe to Email Updates

Trending Posts

Most Popular Posts

Pharmaceutical Research and Manufacturers of America®
950 F Street, NW Suite 300, Washington, DC 20004

Please be advised that this page contains pixel tags. To learn more about what pixel tags are, why and how
we and third parties use pixel tags, and how that use affects you, visit our privacy policy and review
"1. Information Collection."